Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Company Overview

Emmaus Life Sciences, Inc. is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America. The company’s commercial strategy leverages partnerships for scalable manufacturing, regulatory support and local distribution capabilities. Beyond its lead therapy, Emmaus is evaluating early-stage assets to expand its portfolio in rare hematology, seeking to bring new treatment options to patients with unmet medical needs.

Founded in 2005 and headquartered in the San Francisco Bay Area, Emmaus Life Sciences is led by a management team with deep expertise in biotechnology, clinical development and regulatory affairs. The company collaborates with global research institutions and patient advocacy groups to support clinical trials, facilitate global access initiatives and ensure that emerging therapies reach underserved populations. Emmaus continues to pursue strategic alliances and licensing opportunities to drive the advancement of its product pipeline worldwide.

Key Stats

• Today's Range: $0.0109 to $0.0116
• 50-Day Range: $0.0105 to $0.0160
• 52-Week Range: $0.00 to $0.05
• Volume: 38,087 shs
• Average Volume: 35,146 shs
• Market Capitalization: $740.89 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Emmaus Life Sciences Stock Analysis - MarketRank™

Emmaus Life Sciences scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Emmaus Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Emmaus Life Sciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emmaus Life Sciences is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the outstanding shares of Emmaus Life Sciences have been sold short.

Short Interest Ratio / Days to Cover

Emmaus Life Sciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emmaus Life Sciences does not currently pay a dividend.

Dividend Growth

Emmaus Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the outstanding shares of Emmaus Life Sciences have been sold short.

Short Interest Ratio / Days to Cover

Emmaus Life Sciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for EMMA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.42% of the stock of Emmaus Life Sciences is held by institutions.

EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed this year?

Emmaus Life Sciences' stock was trading at $0.0085 at the beginning of 2025. Since then, EMMA shares have increased by 36.5% and is now trading at $0.0116.

How were Emmaus Life Sciences' earnings last quarter?

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Thursday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm earned $2.82 million during the quarter.

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emmaus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Matinas Biopharma (MTNB), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:EMMA
• CIK: 822370
• Web: www.emmausmedical.com
• Phone: (310) 214-0065
• Fax: 866-294-2611
• Employees: 60
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.45 million
• Net Margins: -24.20%
• Pretax Margin: -28.35%
• Return on Equity: N/A
• Return on Assets: -14.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $16.65 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.88) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 63,870,000
• Free Float: 41,513,000
• Market Cap: $740.89 thousand
• Optionable: Not Optionable
• Beta: 8.03